An observational study in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Recruiting at 17 sites in South Korea. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis — 9 open to participants now, 13 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Novartis.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 6th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2023, is one of 19 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 77th registered.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →9 of the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
Novartis Pharmaceuticals · Sites in Germany
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18–99
Novartis Pharmaceuticals · Sites in Saudi Arabia
Ages 18–99
Novartis Pharmaceuticals · Sites in France
Ages 18–99
By country, each count listing its studies:
Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20 · Phase 4 13
First in 1999; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 135 across 148 observational studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 84 across the 63 interventional studies, 400 across the 19 observational. Of the 73 that completed or were terminated, 35 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
5 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06092879Novartis PharmaceuticalsAsciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | 2026-12-15 |
| NCT06684964Novartis PharmaceuticalsRWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL) | 2026-12-30 |
| NCT07454850Novartis PharmaceuticalsA Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait | 2027-07-02 |
| NCT07681258Novartis PharmaceuticalsA Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region | 2027-09-01 |
| NCT04925479Novartis PharmaceuticalsStudy to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | 2027-09-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
The dosage and duration of treatment may be considered and decided by the investigator in accordance with prescribing information of Asciminib.
This study will enroll all patients by total enumeration for those prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice for 2 years after the market launch.
Patients who are going to receive Scemblix® for the first time or those who are currently taking Scemblix® per clinical judgment are eligible and will be prescribed with Scemblix® under routine medical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice
Other: Asciminib
There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
Also known as: Scemblix
Percentage of participants with an AE / ADR
Percentage of participants with an adverse event (AE)/ adverse drug reaction (ADR)
Time frame: 24 weeks
Percentage of participants with a SAE / SADR
Percentage of participants with a serious AE (SAE)/ serious ADR (SADR)
Time frame: 24 weeks
Percentage of participants with an UAE/ UADR
Percentage of participants with an unexpected AE (UAE)/ unexpected ADR (UADR)
Time frame: 24 weeks
Percentage of participants with a SUAE/ SUADR
Percentage of participants with a serious unexpected AE (SUAE)/ serious unexpected ADR (SUADR)
Time frame: 24 weeks
Major molecular response rate
Major molecular response (MMR) rate at week 12 and week 24
Time frame: week 12, week 24
Molecular response 4 rate
Molecular response 4 (MR4) rate. Molecular response (MR) is a Breakpoint Cluster Region protein Tyrosine-protein kinase ABL1 (BCR-ABL1) transcript that is assessed by real-time quantitative PCR (RQ-PCR) in the blood at screening. Molecular response levels are indicated with a superscript indicating the log reduction from the standardized baseline, corresponding to 100% on the international scale (IS).
Time frame: week 12, week 24
Molecular response 4.5 rate
Molecular response 4.5 (MR4.5) rate. Molecular response (MR) is a Breakpoint Cluster Region protein Tyrosine-protein kinase ABL1 (BCR-ABL1) transcript that is assessed by real-time quantitative PCR (RQ-PCR) in the blood at screening. Molecular response levels are indicated with a superscript indicating the log reduction from the standardized baseline, corresponding to 100% on the international scale (IS).
Time frame: week 12 ,week 24
Number of participants with CCyR and/or BCR-ABL1 IS<1%
Complete cytogenetic response (CCyR) rate and/or BCR-ABL1 IS\<1%. A complete cytogenetic response (CCyR) is defined as absence of the Ph (0%) among at least 20 cells in metaphase in a bone marrow aspirate.
Time frame: week 12,week 24
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2030, 82 months after the start.
Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 82 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →